CTRI/2010/091/001346已完成4 期
Assessment of efficacy, safety and tolerability of fixed dose combination Wunder eye Cream (3% Biophytex LS 8740 and 5% Proteasyl TP LS 8657) in the treatment of Under Eye Dark Circles (Infra-orbital hyperchromia)
Glenmark Pharmaceutical limited0 个研究点目标入组 500 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Pms
入排标准
入选标准
- •Subjects eligible for enrolment in the study must meet all the following criteria.
- •Subjects with mild, moderate or severe under eye dark circles
- •Subjects must be 18-50 years of age
- •Subjects must provide written informed consent and comply to the protocol
排除标准
- •Subjects meeting any of the following criteria must not be enrolled in the clinical study.
- •Subjects not willing to discontinue all topical treatments for ?Under Eye? dark circles for 2 weeks prior to enrollment in study
- •Hypersensitivity to any ingredients of Wunder Eye cream
- •Pregnant and lactating women
- •Subjects taking Concomitant therapy* that might interfere with the study results
- •Subjects with dermatological disorder of face that may interfere with study evaluation
- •Subjects who have undergone any surgical treatment of the face
- •*Concomitant topical therapy in under eye area that causes hypopigmentation, includes Retinoids and Hyroquinone skin peels.
- •*Concomitant medicines, that causes hyper pigmentation, includes Phenothiazines, Anti-malarials (Chloroquine), Phenytoin sodium, Cytotoxic drugs, Sulphonamides.
研究者
相似试验
已完成
4 期
A clinical trial to assess the efficacy, safety and tolerability of tigecycline in adult hospitalized patients with community acquired pneumonia (CAP).CTRI/2010/091/001439Glenmark Pharmaceuticals Limited120
进行中（未招募）
不适用
Evaluation of efficacy, safety and tolerability of an ADd-on therapy with Cianocabalamine Vitamin B12 plus Calcium levofolinate in relapsing-remitting multiple sclerosis patients Already in treatment with Nterferon beta over a period of 24 months for a better lonterm outComE - ADVANCEMULTIPLE SCLEROSISEUCTR2005-006071-12-ITAZIENDA OSPEDALIERA SAN CAMILLO FORLANINI276
进行中（未招募）
1 期
Phase 2b study evaluating efficacy, safety and tolerability of study drug called NGM282 (Aldafermin) in Patients with Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisCompensated Cirrhosis Due to Nonalcoholic SteatohepatitisMedDRA version: 22.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 20.1Level: LLTClassification code 10064844Term: Compensated cirrhosisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2019-002341-38-FRGM Biopharmaceuticals, Inc.150
已完成
不适用
study on low back paiCTRI/2016/10/007348Dr Reddys Laboratories Pvt Ltd
进行中（未招募）
1 期
Phase 2b study evaluating efficacy, safety and tolerability of study drug called NGM282 (Aldafermin) in Patients with Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisEUCTR2019-002341-38-BEGM Biopharmaceuticals, Inc.150